[go: up one dir, main page]

WO2007095288A3 - Compositions protéiques ou peptidiques protéine contenant de la méthionine et leur procédé de fabrication et d'utilisation - Google Patents

Compositions protéiques ou peptidiques protéine contenant de la méthionine et leur procédé de fabrication et d'utilisation Download PDF

Info

Publication number
WO2007095288A3
WO2007095288A3 PCT/US2007/003905 US2007003905W WO2007095288A3 WO 2007095288 A3 WO2007095288 A3 WO 2007095288A3 US 2007003905 W US2007003905 W US 2007003905W WO 2007095288 A3 WO2007095288 A3 WO 2007095288A3
Authority
WO
WIPO (PCT)
Prior art keywords
methionine
methods
containing protein
peptide
making
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/003905
Other languages
English (en)
Other versions
WO2007095288A2 (fr
Inventor
Thomas E Tarara
Cynthia Stevenson
Stewart Thompson
Reinhard Vehring
Negar Sadrzadeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Priority to EP07750726A priority Critical patent/EP1986674A4/fr
Publication of WO2007095288A2 publication Critical patent/WO2007095288A2/fr
Publication of WO2007095288A3 publication Critical patent/WO2007095288A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions protéiques ou peptidiques contenant de la méthionine pouvant comporter au moins une protéine ou un peptide contenant de la méthionine et au moins un antioxydant inhibiteur de l'oxydation dudit peptide ou de ladite protéine contenant de la méthionine, les compositions étant inhalables. Des particules peuvent présenter une surface enrichie d'un excipient de surface ayant une température de transition vitreuse et un noyau enrichi d'au moins une protéine ou un peptide contenant de la méthionine. L'invention concerne également des procédés de fabrication, des procédés de traitement et des formes posologiques.
PCT/US2007/003905 2006-02-13 2007-02-13 Compositions protéiques ou peptidiques protéine contenant de la méthionine et leur procédé de fabrication et d'utilisation Ceased WO2007095288A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07750726A EP1986674A4 (fr) 2006-02-13 2007-02-13 Compositions protéiques ou peptidiques protéine contenant de la méthionine et leur procédé de fabrication et d'utilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77338406P 2006-02-13 2006-02-13
US60/773,384 2006-02-13

Publications (2)

Publication Number Publication Date
WO2007095288A2 WO2007095288A2 (fr) 2007-08-23
WO2007095288A3 true WO2007095288A3 (fr) 2008-07-03

Family

ID=38372110

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/003905 Ceased WO2007095288A2 (fr) 2006-02-13 2007-02-13 Compositions protéiques ou peptidiques protéine contenant de la méthionine et leur procédé de fabrication et d'utilisation

Country Status (2)

Country Link
EP (1) EP1986674A4 (fr)
WO (1) WO2007095288A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2621264A1 (fr) * 2005-09-06 2007-11-15 Zelos Therapeutics, Inc. Analogues de l'hormone parathyroidienne et procedes les utilisant
WO2008145323A1 (fr) * 2007-05-31 2008-12-04 F. Hoffmann-La Roche Ag Formulation pharmaceutique comprenant des interférons
AU2009203809B2 (en) 2008-01-09 2013-07-25 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
JP5364310B2 (ja) * 2008-07-14 2013-12-11 アルフレッサファーマ株式会社 反応性物質が結合した微小粒子の安定化方法および該微小粒子含有試薬
HUE068164T2 (hu) 2008-10-17 2024-12-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
CA2780460C (fr) 2009-11-13 2018-09-04 Sanofi-Aventis Deutschland Gmbh Composition pharmaceutique comprenant un agoniste de glp-1, une insuline et de la methionine
FR2954325B1 (fr) * 2009-12-23 2012-02-03 Flamel Tech Sa Polymere amphiphile fonctionnalise par la methionine
EP2364690A1 (fr) * 2010-02-12 2011-09-14 Centro De Ingenieria Genetica Y Biotecnologia Granulé pharmaceutique pouvant être administré par voie orale du facteur de croissance épidermique
RS55378B1 (sr) 2010-08-30 2017-03-31 Sanofi Aventis Deutschland Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
ES2833277T3 (es) * 2011-06-07 2021-06-14 Asahi Kasei Pharma Corp Preparación liofilizada que contiene PTH de alta pureza y método para producirla
DK2739268T3 (en) * 2011-08-01 2019-02-25 Univ Monash PROCEDURE AND FORMULATION FOR INHALATION
BR112014004726A2 (pt) 2011-08-29 2017-04-04 Sanofi Aventis Deutschland combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
MY174679A (en) * 2013-03-13 2020-05-06 Genentech Inc Formulations with reduced oxidation
US20140314778A1 (en) 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
EP3091995B1 (fr) 2014-01-09 2024-03-20 Sanofi Formulations pharmaceutiques stabilisées d'insuline aspart
WO2015104311A1 (fr) 2014-01-09 2015-07-16 Sanofi Formulations pharmaceutiques stabilisées sans glycérol d'analogues de l'insuline et/ou de dérivés de l'insuline
SG11201604706TA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized pharmaceutical formulations of insulin aspart
CA2965759C (fr) 2014-10-31 2023-12-12 Glaxosmithkline Intellectual Property Development Limited Polypeptides en poudre presentant moins d'impuretes de disulfide comprenant des materiaux cationiques divalents
TWI758239B (zh) 2014-12-12 2022-03-21 德商賽諾菲阿凡提斯德意志有限公司 甘精胰島素/利司那肽固定比率配製劑
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US6518239B1 (en) * 1999-10-29 2003-02-11 Inhale Therapeutic Systems, Inc. Dry powder compositions having improved dispersivity
US6541450B1 (en) * 1994-06-20 2003-04-01 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100291620B1 (ko) * 1992-09-29 2001-10-24 추후제출 부갑상선호르몬의활성단편의폐를통한전달방법
MXPA05012821A (es) * 2003-05-28 2006-02-13 Nektar Therapeutics Formulacion farmaceutica que comprende un agente activo insoluble en agua.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US6541450B1 (en) * 1994-06-20 2003-04-01 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US6518239B1 (en) * 1999-10-29 2003-02-11 Inhale Therapeutic Systems, Inc. Dry powder compositions having improved dispersivity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1986674A4 *

Also Published As

Publication number Publication date
EP1986674A2 (fr) 2008-11-05
EP1986674A4 (fr) 2009-11-11
WO2007095288A2 (fr) 2007-08-23

Similar Documents

Publication Publication Date Title
WO2007095288A3 (fr) Compositions protéiques ou peptidiques protéine contenant de la méthionine et leur procédé de fabrication et d'utilisation
ZA200703561B (en) Methods and compositions for improving recombinant protein production
WO2008121767A3 (fr) Polypeptides cousus
MX2010009850A (es) Analogos de insulina acilados y etabilizados contra proteasas.
TWI348891B (en) Composition for preventing plant diseases and method for preventing the diseases
WO2008104306A3 (fr) Amides de 4-aryl-1,4-dihydro-1,6-naphthyridine substitués et utilisation de ceux-ci
WO2009129246A3 (fr) Compositions et leurs procédés de préparation et d'utilisation
JO2576B1 (en) Antibodies
WO2007146965A3 (fr) Composés destinés au traitement d'une maladie périodontale
PL1854477T3 (pl) Peptydy hamujące kalikreinę osoczową do zastosowania w leczeniu zaburzeń okulistycznych
PL1913138T3 (pl) Sposoby wytwarzania pankreatyny w proszku o niskiej zawartości wirusa
WO2006119329A3 (fr) Compositions et procedes pour traiter des maladies neurodegeneratives
WO2005118511A3 (fr) Composes, compositions et methodes permettant de stabiliser la transthyretine et d'inhiber un mauvais repliement de la transthyretine
WO2008066630A3 (fr) Procédés de reprogrammation de cellules somatiques adultes, et leurs utilisations
AP2011005814A0 (en) Gene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseases.
ZA200707407B (en) Composition for preventing plant diseases and method for preventing the diseases
WO2006113568A8 (fr) Combinaison de tramadol et de matieres renfermant la gabapentine
WO2008059041A3 (fr) Complémentation d'un déficit de facteur xi par mutants de facteur v
EP1731139A4 (fr) Preparation pharmaceutique de type s/o et procede de production associe
EP1834624A4 (fr) Préparation thérapeutique et procédé d'élaboration de ladite préparation
SI1838716T1 (sl) Olanzapin pamoat dihidrat
WO2006020430A8 (fr) Nouvelle composition et procedes destines au traitement d'une maladie immunitaire
EP2005964A4 (fr) Médicament pour traiter l'hyperphosphatémie et son procédé de préparation
PL1912513T3 (pl) Nowe frakcje białek mleka i ich zastosowanie do zapobiegania lub leczenia przewlekłych chorób zapalnych
WO2007102946A3 (fr) Polypeptides cristallins

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007750726

Country of ref document: EP